Biotech | April 06, 2022
BioFluidica to introduce next-generation biomarker isolation platform
BioFluidica LiquidScan harnesses the power of microfluidics
BioFluidica LiquidScan harnesses the power of microfluidics
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Subscribe To Our Newsletter & Stay Updated
